Activation of the complement system by nanoparticles and strategies for complement inhibition

被引:1
作者
Haroon, Hajira B. [1 ,2 ]
Dhillon, Elisha [1 ]
Farhangrazi, Z. Shadi [3 ,4 ]
Trohopoulos, Panagiotis N. [5 ]
Simberg, Dmitri [6 ,7 ]
Moghimi, S. Moein [1 ,2 ,7 ]
机构
[1] Newcastle Univ, Sch Pharm, Newcastle Upon Tyne NE1 7RU, England
[2] Newcastle Univ, Translat & Clin Res Inst, Fac Hlth & Med Sci, Newcastle Upon Tyne NE2 4HH, England
[3] SM Discovery Grp Inc, Denver, CO USA
[4] SM Discovery Grp Ltd, Durham, England
[5] CosmoPHOS Ltd, Thessaloniki, Greece
[6] Univ Colorado, Anschutz Med Ctr, Skaggs Sch Pharm, Dept Pharmaceut Sci,Translat Bionanosci Lab, Aurora, CO USA
[7] Univ Colorado, Colorado Ctr Nanomed & Nanosafety, Anschutz Med Ctr, Aurora, CO USA
关键词
Complement; Complement inhibitors; Complement regulators; Complement receptors; Complosome; Nanoparticles; Opsonisation; C3; PATHWAY; BINDING; COMPONENT; RESPONSES; ANAPHYLATOXIN; ANTIBODIES; PROTEINS; SURFACES;
D O I
10.1016/j.ejpb.2023.11.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The complement system is a multicomponent and multifunctional arm of the innate immune system. Complement contributes to non-specific host defence and maintains homeostasis through multifaceted processes and pathways, including crosstalk with the adaptive immune system, the contact (coagulation) and the kinin systems, and alarmin high-mobility group box 1. Complement is also present intracellularly, orchestrating a wide range of housekeeping and physiological processes in both immune and nonimmune cells, thus showing its more so-phisticated roles beyond innate immunity, but its roles are still controversial. Particulate drug carriers and nanopharmaceuticals typically present architectures and surface patterns that trigger complement system in different ways, resulting in both beneficial and adverse responses depending on the extent of complement activation and regulation as well as pathophysiological circumstances. Here we consider the role of complement system and complement regulations in host defence and evaluate the mechanisms by which nanoparticles trigger and modulate complement responses. Effective strategies for the prevention of nanoparticle-mediated complement activation are introduced and discussed.
引用
收藏
页码:227 / 240
页数:14
相关论文
共 95 条
  • [1] Nanoparticles in the clinic: An update
    Anselmo, Aaron C.
    Mitragotri, Samir
    [J]. BIOENGINEERING & TRANSLATIONAL MEDICINE, 2019, 4 (03)
  • [2] Complement Activation by Polymers Carrying Hydroxyl Groups
    Arima, Yusuke
    Kawagoe, Masako
    Toda, Mitsuaki
    Iwata, Hiroo
    [J]. ACS APPLIED MATERIALS & INTERFACES, 2009, 1 (10) : 2400 - 2407
  • [3] Human serum IgM glycosylation - Identification of glycoforms that can bind to mannan-binding lectin
    Arnold, JN
    Wormald, MR
    Suter, DM
    Radcliffe, CM
    Harvey, DJ
    Dwek, RA
    Rudd, PM
    Sim, RB
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (32) : 29080 - 29087
  • [4] Complement activation, regulation, and molecular basis for complement-related diseases
    Bajic, Goran
    Degn, Soren E.
    Thiel, Steffen
    Andersen, Gregers R.
    [J]. EMBO JOURNAL, 2015, 34 (22) : 2735 - 2757
  • [5] C4a: An Anaphylatoxin in Name Only
    Barnum, Scott R.
    [J]. JOURNAL OF INNATE IMMUNITY, 2015, 7 (04) : 333 - 339
  • [6] Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway
    Barratt, Jonathan
    Weitz, Ilene
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [7] Anti-PEG antibodies before and after a first dose of Comirnaty? (mRNA-LNP-based SARS-CoV-2 vaccine)
    Bavli, Yaelle
    Chen, Bing-Mae
    Gross, Guy
    Hershko, Alon
    Turjeman, Keren
    Roffler, Steve
    Barenholz, Yechezkel
    [J]. JOURNAL OF CONTROLLED RELEASE, 2023, 354 : 316 - 322
  • [8] Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population
    Benasutti, Halli
    Wang, Guankui
    Vu, Vivian P.
    Scheinman, Robert
    Groman, Ernest
    Saba, Laura
    Simberg, Dmitri
    [J]. BIOCONJUGATE CHEMISTRY, 2017, 28 (11) : 2747 - 2755
  • [9] PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA (PNH) IS CAUSED BY SOMATIC MUTATIONS IN THE PIG-A GENE
    BESSLER, M
    MASON, PJ
    HILLMEN, P
    MIYATA, T
    YAMADA, N
    TAKEDA, J
    LUZZATTO, L
    KINOSHITA, T
    [J]. EMBO JOURNAL, 1994, 13 (01) : 110 - 117
  • [10] Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]